# Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

> **NCT04662528** · PHASE3 · WITHDRAWN · sponsor: **Matinas Biopharma, Inc**

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** MAT9001 (omega-3 pentaenoic acid)

## Key facts

- **NCT ID:** NCT04662528
- **Lead sponsor:** Matinas Biopharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06
- **Primary completion:** 2022-08
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** suspended
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662528, "Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04662528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*